MAO-B Elevation in Mouse Brain Astrocytes Results in Parkinson's Pathology
Open Access
- 20 February 2008
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 3 (2) , e1616
- https://doi.org/10.1371/journal.pone.0001616
Abstract
Age-related increases in monoamine oxidase B (MAO-B) may contribute to neurodegeneration associated with Parkinson's disease (PD). The MAO-B inhibitor deprenyl, a long-standing antiparkinsonian therapy, is currently used clinically in concert with the dopamine precursor L-DOPA. Clinical studies suggesting that deprenyl treatment alone is not protective against PD associated mortality were targeted to symptomatic patients. However, dopamine loss is at least 60% by the time PD is symptomatically detectable, therefore lack of effect of MAO-B inhibition in these patients does not negate a role for MAO-B in pre-symptomatic dopaminergic loss. In order to directly evaluate the role of age-related elevations in astroglial MAO-B in the early initiation or progression of PD, we created genetically engineered transgenic mice in which MAO-B levels could be specifically induced within astroglia in adult animals. Elevated astrocytic MAO-B mimicking age related increase resulted in specific, selective and progressive loss of dopaminergic neurons in the substantia nigra (SN), the same subset of neurons primarily impacted in the human condition. This was accompanied by other PD-related alterations including selective decreases in mitochondrial complex I activity and increased mitochondrial oxidative stress. Along with a global astrogliosis, we observed local microglial activation within the SN. These pathologies correlated with decreased locomotor activity. Importantly, these events occurred even in the absence of the PD-inducing neurotoxin MPTP. Our data demonstrates that elevation of murine astrocytic MAO-B by itself can induce several phenotypes of PD, signifying that MAO-B could be directly involved in multiple aspects of disease neuropathology. Mechanistically this may involve increases in membrane permeant H2O2 which can oxidize dopamine within dopaminergic neurons to dopaminochrome which, via interaction with mitochondrial complex I, can result in increased mitochondrial superoxide. Our inducible astrocytic MAO-B transgenic provides a novel model for exploring pathways involved in initiation and progression of several key features associated with PD pathology and for therapeutic drug testing.Keywords
This publication has 67 references indexed in Scilit:
- Nigrostriatal Dopaminergic Neurodegeneration in theWeaverMouse Is Mediated via Neuroinflammation and Alleviated by Minocycline AdministrationJournal of Neuroscience, 2006
- Dopamine induces ERK activation in renal epithelial cells through H2O2 produced by monoamine oxidaseKidney International, 2001
- Mortality in DATATOP: A Multicenter trial in early Parkinson's diseaseAnnals of Neurology, 1998
- Cloning/brain localization of mouse glutamylcysteine synthetase heavy chain mRNANeuroReport, 1997
- Hydrogen peroxide mediates amyloid β protein toxicityCell, 1994
- Ultrastructure of spared dopamine terminals in caudate-putamen nuclei of adult rats neonatally treated with intranigral 6-hydroxydopamineDevelopmental Brain Research, 1992
- An Interim Report of the Effect of Selegiline (L -Deprenyl) on the Progression of Disability in Early Parkinson’s DiseaseEuropean Neurology, 1992
- AGEING AND PARKINSON'S DISEASE: SUBSTANTIA NIGRA REGIONAL SELECTIVITYBrain, 1991
- Isolation of Monoaminergic Synaptosomes from Rat Brain by ImmunomagnetophoresisJournal of Neurochemistry, 1991
- The effect of age on the activity and molecular properties of human brain monoamine oxidaseJournal Of Neural Transmission-Parkinsons Disease and Dementia Section, 1980